EZH2 and neoplasm: Regarding KMT5A (monomethylates lysine 20 of histone H4–H4K20me1), low protein expression associated with better prognosis [53], whereas KMT6A/EZH2 (enhancer of zeste homolog 2, involved in the methylation of lysine 9 of histone H3, as well as in the mono-, di- and trimethylation of lysine 27 of histone H3–H3K27me1, H3K27me2 and H3K27me3, respectively) expression levels were up-regulated in tumour tissue comparatively to paired normal epithelium, positively associating with late tumour stage and lymph node metastasis [48,92].